Dr. Tseng is Chief of Surgical Oncology and Associate Professor of Surgery at Beth Israel Deaconess Medical Center. Her research focus is on predicting risk for hepatopancreaticobiliary (HPB) and upper GI malignancy and related diseases, as well as assessing the risks and benefits of various modalities employed in their treatment. Using large national databases, Dr. Tseng has led research on perioperative morbidity and mortality for pancreatic cancer and for pancreatectomy. Disparities in diagnosis, receipt of care, and outcome are under active investigation. She has also used national data to build simple risk scores for HPB surgery that can be easily calculated by hand, computer, or handheld. Dr. Tseng has used institutional data to explore predictors of receiving care; learning curves in surgery; neoadjuvant therapy prior to surgical resection; and vascular resection in order to allow for more potentially curative surgery. With the goal of integrating molecular information in risk prediction and determining best strategies for individual patients, Dr. Tseng has established a novel pancreatic biobank, with whole blood, serum, plasma, and patient tissues, together with potentially biomarker-rich fluids such as pancreatic juice and cystic fluid. In collaboration with basic scientists, she has embarked on microRNA and proteomic profiling of these fluids to identify markers of malignancy as well as response to therapy.